Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...
Fireship on MSN
10 JavaScript Changes You've Missed Last Year
How has JavaScript and web development changed in 2023? Learn about the top 10 updates to Next.js, React, Angular, Vue, and Node.js.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback